GH Research (NASDAQ:GHRS) Trading Up 3.3% – What’s Next?

GH Research PLC (NASDAQ:GHRS) was up 3.3% during trading on Monday . The stock traded as high as $8.00 and last traded at $7.90. Approximately 18,973 shares changed hands during trading, a decline of 76% from the average daily volume of 79,986 shares. The stock had previously closed at $7.65.

Wall Street Analyst Weigh In

Several research analysts have commented on GHRS shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of GH Research in a research note on Thursday, September 5th. JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th.

GH Research Stock Up 5.2 %

The firm’s 50 day simple moving average is $8.32 and its 200 day simple moving average is $10.63. The company has a market capitalization of $418.83 million, a PE ratio of -12.74 and a beta of 0.79.

GH Research (NASDAQ:GHRS) last issued its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. As a group, sell-side analysts predict that GH Research PLC will post -0.89 EPS for the current fiscal year.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. grew its stake in shares of GH Research PLC (NASDAQ:GHRS) by 11.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,251,714 shares of the company’s stock after purchasing an additional 664,381 shares during the quarter. RA Capital Management L.P. owned approximately 12.02% of GH Research worth $66,643,000 at the end of the most recent quarter. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).